Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action | ONCY Stock News

2 days ago

Oncolytics Biotech (ONCY, Financial) to present new pancreatic cancer data at ASCO 2025 in Chicago.
Pelareorep demonstrates encouraging anti-tumor activity in pancreatic ductal adenocarcinoma (PDAC).
The presentation will occur on June 2, 2025, detailing pelareorep's ability to activate immune responses.

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced it will showcase new data from Cohort 1 of the GOBLET study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The data will highlight pelareorep's promising anti-tumor activity in pancreatic ductal adenocarcinoma (PDAC), the most common and challenging form of pancreatic cancer.

According to Dr. Thomas Heineman, Chief Medical Officer of Oncolytics Biotech, pelareorep has demonstrated its potential to improve patient outcomes by engaging the immune system to attack pancreatic cancer tumors. This could be a significant development for patients struggling with this hard-to-treat disease.

The presentation, Abstract #2562, titled "Role of pelareorep in activating anti-tumor immunity in PDAC," will be delivered in a poster format during the Developmental Therapeutics – Immunotherapy session on June 2, 2025, from 1:30 - 4:30 p.m. CT.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.